Alexander Pickett is Managing Director at Juvenescence, where he oversees new opportunity onboarding. Since 2014, he has worked with Juvenescence founding partners Greg, Jim, and Declan at Mediqventures, Ltd., a multi-family investment partnership and merchant bank where he supported existing investments at Portage Biotech Inc., including Portage Pharma Ltd. and Biohaven (NYSE:BHVN).
Alexander worked with Ian Walters to help found SalvaRx Limited, a cancer immunotherapy-focused investment company that was later merged into Portage Biotech.
Prior to joining Mediqventures, Alexander was an associate at Flatley Venture Capital, a cystic fibrosis-focused investment arm of the John J Flatley Company, where he was responsible for investment analysis and scientific due diligence. Alexander co-founded Real Life Sciences, a start-up focused on software-based patient-engagement solutions to improve patient recruitment to clinical trials.
Alexander has a BA in Molecular and Cellular Biology from Harvard College, where he was a Microbial Studies Initiative Undergraduate Fellow and a team member in the International Genetically Engineered Machines Competition.
Alexander’s choice of physical pursuits takes him to the mountains. He is an avid skier.